Glossary

How to Use This

Regulatory (15)  ·  Clinical (17)  ·  CMC & Quality (8)  ·  Commercial (7)  ·  Program management (8)

55 terms across 5 domains, alphabetical within each. Where a term is commonly misunderstood, the entry says so in amber — 40 of 55 entries carry one.

Regulatory 15 terms

505(b)(1)

A full New Drug Application in which all safety and effectiveness data were generated by or for the sponsor.

BLA — Biologics License Application

The equivalent pathway for a biologic. Not used here — VTX-401 is a small molecule peptide filed as an NDA.

CDER — Center for Drug Evaluation and Research

The FDA center responsible for reviewing small-molecule drug applications, including this one.

eCTD — electronic Common Technical Document

The five-module structure every submission is assembled into.

⚠ Module 2 holds the SUMMARIES and is written last, read first.

Expedited programs — Fast Track, Breakthrough, Accelerated Approval, Priority Review

Four distinct mechanisms for shortening development or review, each with its own eligibility test.

⚠⚠ Not a menu to opt into. Each requires evidence the program may not have, and Accelerated Approval buys speed by taking on confirmatory obligations.

Filing date

60 days after submission, when the agency accepts the application for review.

⚠⚠ The PDUFA clock runs from the FILING date, not the submission date — 10 months for a standard NME review, so 12 from submission.

IND — Investigational New Drug application

The application that permits human dosing to begin.

⚠ Not an approval. It is a 30-day non-objection; the agency permits rather than endorses.

iPSP — initial Pediatric Study Plan

The agreed plan discharging PREA obligations, usually with a post-approval deferral.

NME — New Molecular Entity

An active moiety never previously approved. Carries 5 years NCE exclusivity.

Orphan designation

A status for drugs treating rare conditions, carrying 7 years of market exclusivity.

⚠ Not available here — chronic weight management is not a rare disease.

PAI — Pre-Approval Inspection

Inspection of the named manufacturing sites, conducted before approval is granted.

PDUFA date — Prescription Drug User Fee Act

The date by which the agency aims to complete its review. Also called the action date.

⚠ A goal, not a statutory deadline — and it is met the overwhelming majority of the time, which is why programs plan against it.

PMR / PMC — Post-Marketing Requirement / Commitment

Studies after approval. A requirement is imposed; a commitment is agreed.

⚠⚠ Not interchangeable. A missed PMR is a compliance matter; a missed PMC is a conversation.

Refuse-to-file

The agency declining to begin review because the dossier cannot be reviewed.

⚠⚠ Does not restart the review clock — it REMOVES it. There is no clock until the application is accepted.

Type B meeting

The scheduled FDA meeting category covering pre-IND, end-of-phase and pre-NDA meetings.

Clinical 17 terms

ADaM — Analysis Data Model

Analysis-ready datasets derived from SDTM, with documented derivations.

⚠ Exists so a reviewer can re-run the sponsor's analysis without the sponsor.

Blind data review

Review of the data before unblinding, where analysis populations are assigned.

⚠⚠ The SEQUENCE is the control: populations assigned before unblinding, or the result becomes unfalsifiable.

CRO — Contract Research Organization

The vendor executing trial operations. Meridian, here.

⚠ Accountability for conduct cannot be delegated with the work.

CSR — Clinical Study Report

The complete ICH E3 account of one trial.

⚠ Reports the pre-specified analyses in the pre-specified order, whatever they show.

Database lock

The point at which the clinical database is frozen and no further data may be changed.

⚠ Everything downstream — unblinding, analysis, the CSR, the submission — is gated by it, and it cannot be partially done.

DMC / IDMC — (Independent) Data Monitoring Committee

The independent body with unblinded safety oversight and stopping authority.

⚠⚠ Deliberately unmanageable by the sponsor. It tells the sponsor almost nothing, because explaining a CONTINUE would partially unblind.

ICH E3 / E6 — International Council for Harmonisation

E3 is the CSR structure; E6 is Good Clinical Practice.

Informed consent

The documented process by which a participant agrees to take part, having understood the risks.

⚠⚠ A PROCESS, not a form. The signature evidences a conversation, and an inspector interviews the coordinator about how it was obtained.

IRT / IWRS — Interactive Response Technology

The system that randomizes participants and releases investigational product to sites.

ISS / ISE — Integrated Summary of Safety / Efficacy

Submission-level analyses pooling participants across studies.

⚠⚠ NEW ANALYSES, not compilations of the CSRs. Teams that treat them as assembly budget days for months of work.

Protocol deviation

Any departure from the protocol as approved, whether or not it affected a participant.

⚠ Under-reporting them is a common and highly detectable finding — the monitoring reports in the TMF are reconciled against the CSR.

SAE — Serious Adverse Event

An event meeting regulatory seriousness criteria, with defined reporting clocks.

⚠ 'Serious' is a regulatory classification, not a judgment about severity.

SAP — Statistical Analysis Plan

Fixes what will be analyzed and in what order. Signed before database lock.

⚠⚠ The testing hierarchy set here decides what may ultimately be CLAIMED.

Screen failure

A participant who completes screening but is not randomized.

⚠ Rate is expressed against completed screening, not against everyone approached.

SDTM — Study Data Tabulation Model

Raw study data restructured into the tabulation model regulators require for submission.

Testing hierarchy

The pre-specified order in which endpoints are tested.

⚠⚠ Testing STOPS at the first failure. Everything below becomes descriptive, however favorable it looks.

TMF — Trial Master File

The record evidencing the trial was conducted properly.

⚠ Measured against an expected-document list written BEFORE the documents exist.

CMC & Quality 8 terms

CAPA — Corrective and Preventive Action

The formal, documented response to a quality deviation, covering both the fix and the prevention of recurrence.

CMC — Chemistry, Manufacturing and Controls

Everything about making the product to a consistent standard.

⚠ Gates the filing independently of anything clinical.

Form 483

The list of inspectional observations issued at the close of an FDA inspection.

⚠ Observations, not findings. The response matters as much as the content.

GxP — Good [Clinical/Laboratory/Manufacturing] Practice

The frameworks of regulated practice governing how work is conducted and evidenced.

⚠ A floor, not a quality target — compliance is the entry condition, not the achievement.

Method transfer

Moving a validated analytical method from one laboratory or site to another.

⚠⚠ Routinely underestimated. A validated method carries undocumented practice, and moving it exposes what was never written down.

PPQ — Process Performance Qualification

The runs demonstrating the commercial process performs consistently.

Registration batch

A batch manufactured at commercial scale whose data supports the filing.

Stability

Data demonstrating the product remains within specification over time.

⚠⚠ Accrues at one month per month. It is the one program input that cannot be accelerated by any amount of money or attention.

Commercial 7 terms

Copay assistance

Manufacturer-funded reduction of a patient's out-of-pocket cost.

⚠⚠ Rises automatically when coverage is poor — so a weak access position makes each remaining unit more expensive to sell.

Formulary

A payer's list of covered drugs and the tiers determining what a patient pays.

Gross-to-net

The gap between list price and what the manufacturer actually receives.

⚠⚠ Roughly a quarter of list here. The largest deduction is rebates, which buy formulary POSITION rather than volume.

PBM — Pharmacy Benefit Manager

The intermediary negotiating coverage on behalf of plans.

⚠ Three national PBMs control most covered lives, and they run a procurement.

Prior authorization

A payer requirement that a prescriber justify the prescription before it is covered.

⚠ The main route to access for a product not on formulary — real revenue, and nothing like formulary placement.

TPP — Target Product Profile

The labeling claims the product must achieve to be commercially viable.

⚠ Written at Gate 0 and revised only by governance. It is the requirements baseline.

WAC — Wholesale Acquisition Cost

The published list price before any rebate or discount is applied.

⚠ Almost nobody pays it; net is roughly three quarters of it.

Program management 8 terms

Contingency

Funding held against identified risks and drawn under a named authority.

⚠ Not a slush fund and not the same as management reserve — every draw names the risk or change it funded.

Control account

The level at which cost and schedule are managed and a named owner is accountable.

CPI / SPI — Cost / Schedule Performance Index

Earned value ratios: below 1.0 is unfavorable.

⚠ Computed here on the internal labor envelope only, not the whole program.

Gate

A decision point at which the next stage of work is authorized and funded, or is not.

⚠⚠ Not a milestone and not a quality review. A decision that can only go one way is not a decision.

RACI — Responsible, Accountable, Consulted, Informed

The grid mapping each decision to the people who do it, own it, advise on it and hear about it.

⚠ Exactly one Accountable per row. Two names in that column means nobody is.

RECYCLE

A gate outcome returning the work to the stage it came from to remedy a specific deficiency, then back to the same gate.

⚠ Distinct from HOLD, which pauses without requiring anything to be fixed.

TCPI — To-Complete Performance Index

The cost efficiency required across remaining work to finish on budget.

⚠ The watermelon defense: a program reporting green with TCPI well above 1.0 is forecasting a recovery nobody has planned.

Tranche

The portion of the authorized total released at a single gate, rather than up front.

⚠⚠ The tranche is what makes a gate a decision rather than advice.

Where the Longer Explanations Live

This is deliberately terse. Four artifacts carry the same material at length: the Drug Development Lifecycle Guide for how the domain fits together, the Stage-Gate Methodology Guide for the method, the Statistical Analysis Plan for the testing hierarchy, and Sources & Benchmarks for where the published figures behind this fictional program come from.